Genesis Healthcare Remains Committed to Securing Longterm Stability




Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process centered around current and future patients, residents and staff

KENNETT SQUARE, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) — Following a court ruling on Thurs., Dec. 11 to reopen the auction process in Genesis Healthcare, Inc.’s (Genesis) and its affiliates’ ongoing chapter 11 bankruptcy proceedings, David Harrington, Executive Chairman of the Board of Genesis, reiterated the company’s commitment to securing long-term stability through the court-supervised chapter 11 proceedings, clarified inaccuracies in public conversations surrounding the process, and called on all interested parties to recognize – and respect – the hard work and dedication of the Genesis employees who are continuing to deliver services to the elderly and frail residents and patients that they serve during this protracted restructuring process.

“Genesis has significantly strengthened our operational performance, especially in the past two years, by investing in, designing and implementing a forward-looking, enterprise-wide shift from centralized to local market-based operations,” said Harrington. “The Genesis board, in alignment with the company’s executive leadership team – which has been completely transformed in the past three years – identified the Chapter 11 process as the necessary path to maintain and grow that momentum for years to come to benefit our current and future patients, residents and staff. That belief has not changed.”

As has been widely covered by the media, this is not the first time Genesis has considered bankruptcy proceedings. In 2021, Genesis was actively preparing to file for Chapter 11 bankruptcy. Some of the notable voices weighing in on this week’s proceedings were heavily – and vocally – opposed to a filing in 2021, which was ultimately avoided due to ReGen Healthcare’s $100 million investment into Genesis.

“Much has been made – and alleged – about Joel Landau’s association with Genesis, which did not begin until ReGen’s investment in 2021, which enabled Genesis to avert bankruptcy, as many in the public realm were demanding,” said Harrington. “Prior to 2021, ReGen Healthcare (ReGen) and Mr. Landau had no affiliation with or control over Genesis. The investment by ReGen provided Genesis with a lifeline to try to restructure the company outside of bankruptcy and enabled Genesis to completely revamp its executive leadership team, beginning its ongoing transformation to a nimble, market-based model dedicated to prioritizing resident and patient care.”

Some interested parties have called attention to decisions made by Genesis Healthcare to transfer its owned skilled nursing facilities to Welltower, Inc. in 2011 – fully 10 years prior to ReGen’s investment or Mr. Landau’s affiliation with Genesis (which began in 2021) – and simultaneously to enter into a master lease with Welltower, allowing Genesis to continue operating those facilities.

“I hope everyone will understand that none of the current officers or Board members that were with Genesis in 2011, when the decision was made to transfer real estate ownership to Welltower are still with Genesis today,” said Harrington.

Genesis shares interested parties’ focus on patients, residents and staff, and the importance of safeguarding access to high-quality post-acute care in the communities served by the more than 170 skilled nursing centers and assisted and senior living communities across 17 states operated by Genesis.

“I am proud of how, despite the potential for distraction during this restructuring process, our staff continues to put our mission into action by improving the lives we touch through the delivery of high-quality healthcare and everyday compassion,” said Harrington. “Decisions being made by the bankruptcy court regarding the ultimate purchaser of Genesis do not have anything to do with our commitment to our day-to-day operations, and I hope people will remember that as they continue to weigh in on this process. We are confident that entering into chapter 11 and engaging in fulsome restructuring efforts was and still is in the best interest of our current and future patients, residents and staff, and we take issue with those questioning the integrity of our frontline team members who have dedicated themselves to helping others.”

An independent third party engaged by Genesis to conduct patient satisfaction surveys in 2025 has reported:

• 91% favorable rating for relationship with staff members
• 89% favorable rating for leadership taking important measures to keep them safe
• 87% favorable rating for the amount of interaction with staff

Additionally, Genesis has reduced its overall employee turnover year-over-year by 6%, and is maintaining an overall Google rating of 4.3 out of 5 stars for all Genesis Healthcare, Inc.

Genesis would welcome local, state and federal legislative parties interested in learning more about the care provided at our facilities to contact us to schedule a tour.

Court filings and additional information related to the proceedings, which include a proposed transaction involving a current affiliate, are available at https://dm.epiq11.com/Genesis. Those with questions can call (toll-free in the US) 888-861-3979.

Advisors
McDermott Will & Schulte LLP is serving as legal counsel, Ankura Consulting is providing financial restructuring and Chief Restructuring Officer services (Russell A. Perry and Louis E. Robichaux IV, Co-CROs), and Jefferies is serving as investment banker.

ABOUT GENESIS HEALTHCARE, INC.
Genesis Healthcare, Inc. is a holding company with affiliates that operate skilled nursing facilities and assisted/senior living communities. Its subsidiaries also specialize in contract rehabilitation therapy, respiratory therapy, physician services, and accountable care, collectively referred to as Genesis HealthCare. To learn more, visit www.genesishcc.com.

CONTACT: MEDIA CONTACT
mediainquiry@genesishcc.com

Extendicare Announces December 2025 Dividend of C$0.042 per Share




Extendicare Announces December 2025 Dividend of C$0.042 per Share

MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of December 2025, which is payable on January 15, 2026 to shareholders of record at the close of business on December 31, 2025. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada).

About Extendicare

Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of the growing seniors’ population, inspired by our mission to provide people with the care they need, wherever they call home. We operate a network of 99 long-term care homes (59 owned, 40 under management contracts), deliver approximately 13.5 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 152,100 beds across Canada. Extendicare proudly employs approximately 28,000 qualified, highly trained and dedicated team members who are passionate about providing high-quality care and services to help people live better.

Forward-looking Statements

Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation: statements regarding its dividend levels, business operations, business strategy, growth strategy, results of operations and financial condition. Forward-looking statements can often be identified by the expressions “anticipate”, “believe”, “estimate”, “expect”, “intend”, “objective”, “plan”, “project”, “will”, “may”, “should” or other similar expressions or the negative thereof. These forward-looking statements reflect the Company’s current expectations regarding future results, performance or achievements and are based upon information currently available to the Company and on assumptions that the Company believes are reasonable. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedarplus.ca and on Extendicare’s website at www.extendicare.com. Except as required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Extendicare contact:

Jillian E. Fountain

Vice President, Investor Relations
T: (905) 470-5534
E: jfountain@extendicare.com
www.extendicare.com

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026




Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva’s website at: https://ir.tevapharm.com/Events-and-Presentations.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva’s website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This Document and the presentation at the conferences may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries
TevaIR@Tevapharm.com

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease




Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today provides an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer’s disease.

As per previous communication, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed Anavex about a negative trend-vote following its oral examination in November. As expected, the CHMP has adopted a negative opinion on the marketing authorisation application for blarcamesine to treat Alzheimer’s disease. The Company intends to request a re-examination of the CHMP opinion. The EMA procedures adopted by the CHMP allow an applicant to request re-examination of its decision, which would be undertaken by a different set of reviewers that conduct a new examination, independent from the first opinion.

We believe that the initiated dialogue reinforced our shared commitment to addressing the urgent unmet need in Alzheimer’s disease,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Our team is committed to continue working in partnership with regulatory bodies in order to advance science and potentially new oral treatment options for patients and their families.”

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

About Alzheimer’s disease

Alzheimer’s disease is the most common cause of dementia, accounting for 60-80% of all dementia cases worldwide. Dementia is a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer’s disease is a progressive disease, where symptoms gradually worsen over time. Each stage of the disease presents different challenges for those living with the disease and their care partners. There is a significant unmet need for new treatment options that can slow down the progression of Alzheimer’s disease and reduce the overall burden on people affected and on society.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

GRI Bio Announces Closing of $8.0 Million Public Offering




GRI Bio Announces Closing of $8.0 Million Public Offering

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of common stock (the “Series F Warrants”), at a combined public offering price of $0.75 per share (or per common stock equivalent in lieu thereof) and accompanying Series F Warrant. The Series F Warrants have an exercise price of $0.75 per share and are exercisable immediately upon issuance and will expire on the fifth anniversary of the initial issuance date.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $8.0 million before deducting the placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series F Warrants, if fully exercised on a cash basis, will be approximately $8.0 million. No assurance can be given that any of the Series Warrants will be exercised. The Company intends to use the net proceeds from this offering for its product candidate development, working capital and general corporate purposes.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-291999), as amended, which was declared effective by the Securities and Exchange Commission (the “SEC”) on December 11, 2025. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. Electronic copies of the final prospectus may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the anticipated use of proceeds from the offering; the exercise of the Series F Warrants prior to their expiration; the Company’s ability to maintain compliance with the Nasdaq listing requirements; the Company’s expectations with respect to development and commercialization of the Company’s product candidates; the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) market and other conditions; (2) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (3) changes in applicable laws or regulations; (4) the inability of the Company to raise financing in the future; (5) the success, cost and timing of the Company’s product development activities; (6) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (7) the inability of the Company to identify, in-license or acquire additional technology; (8) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (9) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (10) the failure to achieve any milestones or receive any milestone payments under any agreements; (11) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (12) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (13) other risks and uncertainties indicated from time to time in the Company’s filings with the SEC, including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 92,000 shares of the Company’s common stock to four newly hired employees of the Company, each as an inducement material to each employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

The Inducement Grants each have a ten-year term and an exercise price per share of $6.01, which is equal to the closing price of CAMP4’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.

About CAMP4 Therapeutics 
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com. 

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways




NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways

Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s Exosomes

TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-biotechnology company developing exosome-based therapies for central nervous system injuries, today announced meaningful progress in its long-term clinical-readiness strategy. The Company has begun the process of evaluating potential Israeli production partners to support small-scale GMP-based manufacturing of its lead candidate, ExoPTEN, in order to test the drug in under a First-in-Human Use program, pending regulatory approval.

Dr. Lior Shaltiel, Chief Executive Officer, noted: “ExoPTEN brings together a powerful synergistic impact with highly active exosomes produced, combined with a targeted siRNA. As we advance our manufacturing plans, small clinical grade batches will position us to prepare a First-in-Human use submission in the future, if and when the regulatory pathway supports it.” He added, “ExoPTEN is being developed for both acute spinal cord injury and optic nerve injury, although it has not yet been determined which indication will be prioritized for a first-in-human program.”

In parallel, NurExone reported new scientific data showing strong biological activity in its exosomes compared with commercially available exosomes, reinforcing confidence in the platform as the Company advances toward human studies.

Early Manufacturing in Israel: A Key Step Toward U.S. Scale-Up

NurExone is currently evaluating several Israeli manufacturing organizations with expertise in advanced biologics and Good Manufacturing Practices (“GMP”)-aligned systems for small-scale ExoPTEN manufacturing runs aligned with future clinical requirements.

“This is a strategically important next phase of operational de-risking,” said Dr. Ina Sarel, Head of CMC, Quality and Regulatory Affairs. “Israel is the starting point for our small scale GMP-production of exosomes and process validation, after which exosome production will transition to the United States for scale-up.”

NurExone emphasized that no compassionate-use or clinical manufacturing is being initiated at this stage. All such activities would be subject to regulatory engagement and approval.

New Scientific Data Reinforce Platform Strength

Recent analytical testing demonstrated that NurExone’s exosomes produced from human bone marrow–derived mesenchymal stem cells (“MSC”) exhibit significantly higher CD73-associated biological activity compared with a commercially available MSC exosome control. CD73 is a surface enzyme linked to extracellular signaling and tissue-repair mechanisms.

As shown in the graph below, the average of NurExone’s two manufacturing batches demonstrated meaningfully higher adenosine monophosphate (“AMP”) to adenosine conversion per particle compared with the control. The difference was statistically significant (t-test, p < 0.01), indicating that NurExone’s exosomes possess stronger functional characteristics associated with regenerative potential, or in other words NurExone’s exosomes can send stronger “healing” or “anti-inflammatory” signals.

These findings validate the potency of NurExone’s therapeutic exosomes strengthening the biological rationale for their use as a delivery vehicle in ExoPTEN.

These results demonstrate the high quality of the Master Cell Bank acquired by NurExone and the knowhow held by NurExone and its patented 3D shear-force production technology, indicating that the manufacturing approach described in the patent can yield higher-quality, more potent exosomes in practice.

Engagement of Russo Partners

Subject to TSX Venture Exchange (“TSXV”) approval, NurExone has engaged Russo Partners LLC, a New York–based strategic communications firm, (“Russo”) for an initial consulting project for up to two months for a fixed fee of US$6,600.

Either party may terminate the engagement with 30 days’ notice. Russo does not currently have a direct or indirect interest in the securities of the Company. While Russo has no intention of acquiring any additional securities of the Company at this time, it may do so in the future in compliance with applicable securities laws and TSXV policies.

About Russo Partners

Russo Partners is a strategic communications firm focused on innovators in healthcare and technology. Founded as Noonan/Russo in 1988, the firm collaborates on integrated communications programs for biopharma, MedTech, diagnostics, healthcare IT and healthcare services companies worldwide. The firm’s team is comprised of Ph.D.s, M.D.s., former journalists and members of Wall Street. Russo Partners is known for delivering award-winning strategic counsel and services aligned with its core values of passion, trust, forward-thinking and client focus. For more information, visit www.russopartnersllc.com.

About NurExone

NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsⁱ. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company advancing ExoPTEN’s manufacturing processes and analytical methods; the Company’s evaluating potential Israeli production partners and organizations for early, small‑scale GMP‑aligned manufacturing runs of ExoPTEN; the Company’s preparing for compassionate-use filings once regulatory pathways permit; the Company launching a first compassionate-use and first-in-human programs; expectations associated with the Master Cell Bank and the Company’s patented 3D shear-force production technology; the Company engaging Russo; the Company preparing regulatory submissions; receipt of regulatory approvals, including TSXV approval; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company has the ability to advance ExoPTEN’s manufacturing processes and analytical methods; the Company will prepare regulatory submissions; suitable Israeli manufacturing partners with requisite GMP capabilities will be identified and engaged on acceptable terms; early, small clinical grade batches can and will be produced, characterized and validated in alignment with future regulatory requirements; applicable compassionate-use or expanded-access pathways will be available and that regulatory agencies will accept the Company’s filings; the Master Cell Bank will continue to meet quality, consistency and supply requirements; the patented production approach will operate as intended at planned scales; the engagement of Russo will receive TSXV approval and the consulting services will benefit the Company; the Company has the ability to launch a first compassionate-use and first-in-human programs; and the NurExone platform technology has the ability to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; the inherent uncertainty of preclinical drug development, including challenges in identifying, engaging or retaining qualified manufacturing partners, achieving and maintaining GMP compliance, and producing consistent batches of ExoPTEN; the Company will not file for compassionate-use; the Master Cell Bank will no longer meet quality, consistency and/or supply requirements; the engagement of Russo will not be approved; the Company will not yield the intended benefits from their engagement of Russo; the risk that product candidates may not advance to clinical trials or receive regulatory approval; the possibility that results from preclinical studies and early-stage trials may not predict later outcomes; the uncertain timing, cost, and outcome of preclinical and clinical development activities; risks related to the clinical trial process, including potential delays or failure to achieve effective trial design or positive results; the inability to obtain or maintain required regulatory approvals; limited market acceptance of the Company’s products, even if approved; the potential emergence of competing therapies that are safer, more effective, or more affordable; rapid technological change that may impact the relevance of the Company’s technologies; the Company’s dependence on key personnel and strategic partners; the inability to obtain adequate financing; risks related to the Company’s ability to protect its intellectual property; the possibility that the Company’s technologies, including its exosome-based platforms, may not achieve their intended therapeutic impact; the inability to produce or scale exosome-based products for clinical use; limited adoption in regenerative medicine or cell therapy applications; lack of growing clinical demand in targeted indications such as spinal cord injury, optic nerve repair, or other therapeutic areas; failure to meet planned development milestones or achieve commercial breakthroughs; the Company will not advance the ExoPTEN’s manufacturing processes and/or analytical methods; the Company will not prepare regulatory submissions; the Company will not launch first compassionate-use nor first-in-human programs; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

ⁱ Spinal cord injury, Glaucoma

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d5b187f6-3be5-4601-a83d-d94953a35a13

Park Dental Partners Rings the Closing Bell on the Nasdaq in New York




Park Dental Partners Rings the Closing Bell on the Nasdaq in New York

MINNEAPOLIS, Dec. 12, 2025 (GLOBE NEWSWIRE) — Park Dental Partners, Inc. (“Park Dental Partners” or the “Company”), today announced that on December 11, 2025, members of the Park Dental Partners team rang the closing bell on the Nasdaq Stock Market (“Nasdaq”) in New York to commemorate the successful completion of its recent public listing. The event was broadcast live, allowing potential stakeholders worldwide to join in the celebration. The shares began trading on the NASDAQ Capital Market on December 3, 2025, under the symbol “PARK”. 

“We are in the early stages of our growth strategy and our public offering provided us with the next step in expanding our base of stakeholders to help us deliver on our desire to become a leader in the dental industry,” stated Pete Swenson, Chairman of the Board and Chief Executive Officer. “We are committed to grow our business, while maintaining our strong culture of service to our dentists and patients. It is an exciting time for Park Dental Partners and all of our stakeholders.”

About Park Dental Partners

Park Dental Partners is a dental resource organization that provides comprehensive non-clinical business support services to affiliated general and multi-specialty dental practices across Minnesota and Wisconsin. Through long-term administrative resources agreements, Park Dental Partners supplies clinical support teams, administrative personnel, facilities, equipment, technology, revenue cycle management, and other centralized services that allow affiliated practices to focus on delivering high-quality patient care. Park Dental Partners’ network supports over 200 dentists across 85 practice locations and offers a full range of general and specialty services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/c54a7298-f098-4a2d-9e99-d26536e143d4

https://www.globenewswire.com/NewsRoom/AttachmentNg/a2c74c16-117d-4b7a-99f5-532a674ce0af

CONTACT: Park Dental Partners 
Media Relations 
651-633-0500 
marketing@parkdentalpartners.com

Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup




Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors –

RADNOR, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the manuscript highlighting the Company’s Phase 3 Launch-HTN clinical trial evaluating lorundrostat for the treatment of uncontrolled or treatment-resistant hypertension, was featured in JAMA’s inaugural “Research of the Year Roundup,” a curated collection of the most impactful studies published between October 2024 and September 2025.

In introducing this first-ever “Research of the Year Roundup,” JAMA noted that its top editors were asked to nominate their favorite studies based on their importance and impact. The list of nine selected studies spans diverse topics – from hypertension, to dementia and the use of artificial intelligence (AI) – and, according to JAMA, reflects clinical conditions that are of great importance to patients, clinicians, and to the public health community.

Among this select group, JAMA profiled Mineralys’ Launch-HTN trial under the banner “New Hope for Treatment-Resistant Hypertension.” The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor (ASI), when added to existing background antihypertensive treatment in 1,083 participants with uncontrolled or treatment-resistant hypertension. The trial demonstrated that lorundrostat significantly reduced systolic blood pressure (BP) with a favorable safety and tolerability profile. Launch-HTN recruited a diverse population as reflected in the high proportion of female, Black or African American and elderly participants in the trial.

JAMA highlighted several key findings from the Launch-HTN trial:

• Lorundrostat’s mechanism targets excess aldosterone production, a root cause of hypertension. Unlike existing aldosterone blockers that obstruct the hormone receptor, lorundrostat inhibits the enzyme that produces aldosterone itself, offering a novel mechanism of action.
• When added to existing background treatment, lorundrostat 50 mg dosed once daily demonstrated clinically meaningful, statistically significant mean reductions in automated office blood pressure (AOBP) with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted; p-value < 0.0001) that was sustained with a reduction of 19.0 mmHg at Week 12 (-11.7 mmHg placebo adjusted; p-value < 0.0001). These benefits were consistent across age, sex, race, body mass index, and baseline medication regimen.
• Lorundrostat demonstrated a favorable safety and tolerability profile in the Launch-HTN trial, noting that while hyponatremia, hyperkalemia, and reduced kidney function occurred more frequently in the treatment arm, discontinuation rates due to adverse events remained below 1%.

In the “Research of the Year” article, JAMA’s Executive Editor Gregory Curfman, MD, emphasized the importance of advancing care for the large segment of patients whose hypertension remains uncontrolled despite being on multiple medications, noting that lorundrostat “opens a new approach to the treatment of uncontrolled hypertension, which may affect up to 40% of patients.” The article also points out that, until now, patients have had limited options despite facing heightened cardiovascular risks, including myocardial infarction, stroke, or chronic kidney disease.

“We are honored that JAMA has recognized Launch-HTN as one of its Research of the Year studies,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “This acknowledgment underscores the significant clinical need faced by millions of people living with uncontrolled or treatment-resistant hypertension. The results of Launch-HTN reflect the dedication of our investigators, participants, and team, and reinforce our commitment to bringing forward a differentiated therapy to address a root cause of hypertension.”

The manuscript titled, “Lorundrostat in Participants with Uncontrolled and Treatment-Resistant Hypertension” was featured in JAMA’s June 30, 2025 issue. Lorundrostat continues to be evaluated in the ongoing Transform-HTN open-label extension trial, which is assessing long-term safety and durability of response. The Company also completed enrollment in Explore-OSA, the first trial to evaluate lorundrostat in participants with hypertension and moderate-to-severe OSA. Lorundrostat is the only ASI being studied to address both apnea-hypopnea index (AHI) and nighttime systolic blood pressure in this population, with data anticipated in the first quarter of 2026.

About Launch-HTN
Launch-HTN (NCT06153693) was a global, randomized Phase 3 double-blind, placebo-controlled trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: placebo; lorundrostat 50 mg once daily; or lorundrostat 50 mg once daily with the option to increase to 100 mg at week six. The primary endpoint was change from baseline in systolic BP at six weeks versus placebo, measured by automated office blood pressure monitoring.

About Hypertension

Having sustained, elevated blood pressure (or hypertension) (BP) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertension patients achieve their BP goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat

Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants.

The Company has now completed four successful clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The Company has completed two pivotal, registrational trials, including the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic BP by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Forward Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA); the anticipated timing of NDA submission and the FDA’s review of the same; the Company’s ability to evaluate lorundrostat as a potential treatment for CKD, OSA, uHTN or rHTN; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of participants in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; any delays in the FDA’s review of our planned NDA submission, including as a result of a government shutdown or reductions in agency funding or personnel, the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

DOC HOLLYWOOD: A Psychiatrist Takes 3rd Place with Baxter’s Brain at the American Film Market Pitch Conference




DOC HOLLYWOOD: A Psychiatrist Takes 3rd Place with Baxter’s Brain at the American Film Market Pitch Conference

LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) — Dr. Walter Jacobson, a Los Angeles-based psychiatrist, author, and first-time filmmaker, scored a major win at this year’s American Film Market (AFM) Pitch Conference when his outrageous comedy, Baxter’s Brain, took 3rd place from a panel of industry judges, including award-winning producer Cassian Elwes, screenwriting professor and coach Lee Jessup, and independent producer Loni Rodgers.

The AFM Pitch Conference is one of the market’s signature showcases where selected creators present their concepts live to top producers, financiers, and development executives.​

Walter first came to Hollywood years ago to write movies, but shifted gears to become a psychiatrist after deciding he needed more life experience to tell the stories he wanted to tell.

After 25 years in private practice, he has returned to screenwriting with Baxter’s Brain, a satiric, irreverent, over the top comedy that pokes fun at doctors, TV shows, and “the insanity of our society that has become the new normal.​”

After submitting a 2-minute video to the AFM Pitch Conference committee, Walter was one of 20 filmmakers chosen from over 150 entries to pitch Baxter’s Brain at the Pitch Conference on November 15, 2025.

“The response from the audience to my pitch was incredibly validating,” reports Walter. “It was a great affirmation that Baxter’s Brain is funny and that people will go see it.”

When asked how he feels about his screenwriting skills this second time around, Walter is very clear about this. “I drew from my years as a psychiatrist. Interacting with a wide range of people from all walks of life gave me insights into the quirks of human nature that my younger self didn’t have access to. I am immensely proud of the screenplay and confident that this is a movie that will bring a lot of laughter and joy to the world.”

Joining forces with veteran producer Franco Sama of Samaco Films, Walter has no doubts about Baxter’s Brain becoming a global box office phenomenon and a new comedy franchise. “People love wacky comedies like The Naked Gun and Blazing Saddles,” states Walter. “They are hungry for more and they will go to the theatres in droves if a really funny movie shows up. There is also a separate huge market of people who love movies with talking animals, like TED and Paddington. Baxter is a super-smart, talking gorilla. Audiences will love him! And you can take that to the bank!”

One wonders where Walter’s confidence comes from. “That’s easy. I’ve studied comedy my whole life. I know what’s funny. When I was struggling to make it as a writer, I produced a weekly show, Poor Walter’s Almanac, on cable TV, which was me ranting and raving about everything under the sun. Roseanne and Tom Arnold were fans of the show, as were many celebrities including Richard Lewis, George Carlin, Casey Kasem and Steve Edwards. The point of all this is to say that I made all those people laugh, AND Roseanne brought me onto her ROSEANNE show as a recurring character. So I must know a few things about comedy.”

So what’s next for Baxter’s Brain? “We need to get it financed and produced. I’m hoping this article will inspire the right people to contact me and help me bring Baxter’s Brain to a welcoming public.”

Media Contact

For press materials, partnership inquiries, or interview requests, please contact:

Dig 22 Productions
(310) 628-7222

walterdoc@mac.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7ad218ac-7897-4461-8863-96101c1ef608